A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

In the wake of dramatic cuts to US Department of Health and Human Services (HHS) staff, cutbacks for state public health ...

More than 170,000 people still sought medical help for acute respiratory infection (ARI), including 22,000 with ...

At ESCMID Global 2025 in Vienna, AstraZeneca will present a comprehensive data package from its Vaccines & Immune Therapies portfolio, featur ...

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...

"My daughter was like a walking virus collection," says a visibly exhausted mother in Nairobi. Her four-year-old tested positive for not one, but four different viruses simultaneously – Influenza A, ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

While the ‘official’ flu season may still be a month or two away, reports indicate a rise in respiratory illnesses like the ...